Virus Plaque Assayによる頭頸部悪性腫瘍患者の

概要

論文の詳細を見る
Most of the investigations about immune potential of peripheral blood lymphocytes in cancer patients up to now have been studied with non-specific or tumor specific qualitative mitotic responses in vitro. In order to study immunological responsiveness quantitatively, virus plaque assay devised by B. R. Bloom was applied to determine immune potentials of the patients with head and neck cancer and the normal subjects. It has been reported that by this method the number of activated lymphocytes with a mitogen or antigen could be enumerated. Using this method, the number of Concanavalin A (Con A)-activated lymphocytes in cancer patients was examined. The cancer patient consisted of non-Hodgkin malignant lymphoma (7 cases), lingual cancer (6 cases), laryngeal cancer (5 cases), and miscellaneous (6 cases).The number of virus plaque forming cells (VPFC) activated by Con A was subtracted from that of VPFC without Con A. The subtracted number (AVPFC) in the cancer patients (- 1538 ± 3197, mean ± SD) was significantly smaller than that of 11 normal cases (9727 ± 9009) and 7 cases of benign diseases (12537 ± 23228). The number of AVPFC in the cancer group was generally small regardless to the difference of the primary region of cancer, TNM classification, clinical stage, and the pathological findings. There was no correlation between the number of VPFC and that of peripheral blood lymphocytes in the cancer patients.The advantages of virus plaque assay for immunological investigation in cancer patients were emphasized.
社団法人日本耳鼻咽喉科学会の論文

Virus Plaque Assayによる頭頸部悪性腫瘍患者の

スポンサーリンク

概要

著者

関連論文

スポンサーリンク